Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC2308 | UK 383367 |
| Potent and selective inhibitor of BMP-1 (procollagen C-proteinase; PCP) (IC50 = 44 nM). Selective for BMP-1 over MMPs 1, 2, 3, 9 and 14 (IC50 values are >10,000 nM for listed MMPs). | |
| BCC2309 | Tosedostat (CHR2797) |
| Aminopeptidase inhibitor (IC50 values are 100, 150, 220, > 1000, > 5000, > 10000 and > 30000 nM for LAP, PuSA, aminopeptidase N, aminopeptidase B, PILSAP, LTA4 hydrolase and MetAP2 respectively). Potently inhibits tumor cell proliferation in a variety of tumor cell lines in vitro and in vivo. | |
| BCC2310 | Varespladib (LY315920) |
| Selective secreted phospholipase A2 (sPLA2) inhibitor (IC50 = 50 - 750 nM for a range of sPLA2 isoforms). Has no effect on cytosolic PLA2 or COX-1 and COX-2 activity. Attenuates sPLA2-induced thromboxane formation in bronchoalveolar lavage (BAL) cells. Also suppresses sPLA2-induced contractions of lung pleural strips ex vivo. Orally available. | |
| BCC2312 | U-104 |
| Potent carbonic anhydrase (CA) inhibitor (Ki values are 4.5, 45.1, 5080 and 9640 nM for CA XII, CA IX, CA I and CA II respectively in MDA-MB-231 cells). Inhibits tumor metastasis in the rat 4T1 metastasis model. | |
| BCC2315 | JNJ-1661010 |
| Selective, reversible inhibitor of fatty acid amide hydrolase (FAAH) (IC50 = 12 nM). Brain penetrant and active in vivo. | |
| BCC2317 | Fluvastatin Sodium |
| Orally active, potent and competitive HMG-CoA reductase inhibitor (IC50 = 40 -100 nM at human liver microsomes). Inhibits vascular smooth muscle proliferation in vitro (IC50 = 70 nM) and exhibits antihypercholesterolemic and antioxidant activity in vivo. | |
| BCC2319 | Atorvastatin Calcium |
| Potent HMG-CoA reductase inhibitor (IC50 = 8 nM). Reduces circulating LDL-C by inhibiting cholesterol biosynthesis and inducing expression of LDL receptors. Inhibits smooth muscle cell proliferation in vitro and exhibits antinociceptive effects in the inflammatory hypernociception model. | |
| BCC2321 | Pravastatin sodium |
| Water-soluble, competitive inhibitor of 3-hydroxy-3-methyl coenzyme A (HMG-CoA) reductase. Potently blocks cholesterol synthesis in vivo (Ki~ 1 nM) and displays cardioprotective properties. | |
